We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in ...
Zacks.com on MSN
PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...
Bristol Myers Squibb’sBMY boasts a deep and promising pipeline. Key pipeline candidates with multi-billion-dollar potential are milvexian (Oral factor XIa inhibitor), admilparant (LPA1 antagonist) ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results